Valuation dashboard for Zai Lab Limited (ZLAB) with P/E N/A, P/B 2.76, EV/EBITDA -9.33 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders.
Analysis Summary
Zai Lab Limited reported revenue of $460.2M in the most recent fiscal year, growing at a 5-year CAGR of 56.5%.
Trailing-twelve-month margins: gross margin 58.5%, operating margin -48.6%, net margin -38.1%.
At the current price of $24.67, ZLAB has negative trailing earnings (P/E not meaningful) and an ROE of -24.53%. Market capitalisation stands at $2.8B.
Balance sheet quality for ZLAB: current ratio of 2.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.76 |
| EV / EBITDA | -9.33 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-67.45 |
| vs Current Price | -373.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ZLAB | Zai Lab Limited | $2.8B | 2.76 | -24.5% | |
| CNTA | Centessa Pharmaceuticals plc | $6.3B | 12.76 | -60.4% | |
| SRRK | Scholar Rock Holding Corporation | $5.9B | 22.93 | -160.2% | |
| APGE | Apogee Therapeutics, Inc. | $8.4B | 8.53 | -29.9% | |
| LEGN | Legend Biotech Corporation | $3.1B | 2.57 | -8.7% | |
| IDYA | IDEAYA Biosciences, Inc. | $3.6B | 2.93 | -16.5% | |
| IRON | Disc Medicine, Inc. | $2.6B | 3.78 | -28.7% |
Price
| Price | $24.67 |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | CN |
Profitability
| Return on Equity | -24.53% |
| Return on Invested Capital | -22.74% |
| Return on Assets | -14.97% |
| Gross Margin | 58.47% |
| Operating Margin | -48.59% |
| Net Margin | -38.15% |
Related companies: AAPG · APGE · CDTX · CNTA · IDYA · IRON · LEGN
Explore sector: Healthcare · Biotechnology
More sections of ZLAB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks